Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  COVID-19

  Free Subscription


Articles published in Life Sci

Retrieve available abstracts of 72 articles:
HTML format



Single Articles


    November 2020
  1. SABIRLI R, Koseler A, Goren T, Turkcuer I, et al
    High GRP78 levels in Covid-19 infection: A case-control study.
    Life Sci. 2020 Nov 18:118781. doi: 10.1016/j.lfs.2020.118781.
    PubMed     Abstract available


  2. LANG Y, Chen K, Li Z, Li H, et al
    The nucleocapsid protein of zoonotic betacoronaviruses is an attractive target for antiviral drug discovery.
    Life Sci. 2020 Nov 12:118754. doi: 10.1016/j.lfs.2020.118754.
    PubMed     Abstract available


    October 2020
  3. DHAUNDIYAL A, Kumari P, Jawalekar SS, Chauhan G, et al
    Is highly expressed ACE 2 in pregnant women "a curse" in times of COVID-19 pandemic?
    Life Sci. 2020 Oct 28:118676. doi: 10.1016/j.lfs.2020.118676.
    PubMed     Abstract available


  4. SHRESTHA DB, Budhathoki P, Syed NI, Rawal E, et al
    Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis.
    Life Sci. 2020 Oct 26:118663. doi: 10.1016/j.lfs.2020.118663.
    PubMed     Abstract available


  5. BAKADIA BM, Boni BOO, Ahmed AAQ, Yang G, et al
    The impact of oxidative stress damage induced by the environmental stressors on COVID-19.
    Life Sci. 2020 Oct 26:118653. doi: 10.1016/j.lfs.2020.118653.
    PubMed     Abstract available


  6. PAN ZY, Chang YX, Han N, Hou FY, et al
    Short-term high-dose gavage of hydroxychloroquine changes gut microbiota but not the intestinal integrity and immunological responses in mice.
    Life Sci. 2020 Oct 22:118450. doi: 10.1016/j.lfs.2020.118450.
    PubMed     Abstract available


  7. MORRIS G, Bortolasci CC, Puri BK, Olive L, et al
    Preventing the development of severe CoVID 19 by modifying immunothrombosis.
    Life Sci. 2020 Oct 20:118617. doi: 10.1016/j.lfs.2020.118617.
    PubMed     Abstract available


  8. BAILLY C, Vergoten G
    Mechanistic insights into dimethyl cardamonin-mediated pharmacological effects: A double control of the AMPK-HMGB1 signaling axis.
    Life Sci. 2020 Oct 18:118601. doi: 10.1016/j.lfs.2020.118601.
    PubMed     Abstract available


  9. YADAV P, Vats R, Bano A, Bhardwaj R, et al
    Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics.
    Life Sci. 2020;263:118588.
    PubMed     Abstract available


  10. SATARKER S, Nampoothiri M
    Involvement of the nervous system in COVID-19: The bell should toll in the brain.
    Life Sci. 2020 Oct 6:118568. doi: 10.1016/j.lfs.2020.118568.
    PubMed     Abstract available


  11. MORRIS G, Athan E, Walder K, Bortolasci CC, et al
    Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?
    Life Sci. 2020;262:118541.
    PubMed     Abstract available


    September 2020
  12. VITIELLO A, Ferrara F
    Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19.
    Life Sci. 2020;262:118510.
    PubMed     Abstract available


  13. PENG W, Wu H, Tan Y, Li M, et al
    Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019.
    Life Sci. 2020;262:118496.
    PubMed     Abstract available


  14. SADEGHI S, Soudi S, Shafiee A, Hashemi SM, et al
    Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action.
    Life Sci. 2020;262:118493.
    PubMed     Abstract available


  15. UNUDURTHI SD, Luthra P, Bose RJC, McCarthy J, et al
    Cardiac inflammation in COVID-19: Lessons from heart failure.
    Life Sci. 2020 Sep 21:118482. doi: 10.1016/j.lfs.2020.118482.
    PubMed     Abstract available


  16. BELHASSAN A, En-Nahli F, Zaki H, Lakhlifi T, et al
    Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach.
    Life Sci. 2020 Sep 18:118469. doi: 10.1016/j.lfs.2020.118469.
    PubMed     Abstract available


  17. VINAYAGAM S, Sattu K
    SARS-CoV-2 and coagulation disorders in different organs.
    Life Sci. 2020;260:118431.
    PubMed     Abstract available


  18. KHATRI R, Gupta RK, Vats P, Bansal V, et al
    Subclinical elevated B-type Natriuretic Peptide (BNP) indicates endothelial dysfunction contributing to hypoxia susceptibility in healthy individuals.
    Life Sci. 2020 Sep 11:118408. doi: 10.1016/j.lfs.2020.118408.
    PubMed     Abstract available


  19. CHAUDHRY SN, Hazafa A, Mumtaz M, Kalsoom U, et al
    New insight on possible vaccine development against SARS-CoV-2.
    Life Sci. 2020 Sep 11:118421. doi: 10.1016/j.lfs.2020.118421.
    PubMed     Abstract available


  20. DUERR GD, Heine A, Hamiko M, Zimmer S, et al
    Parameters predicting COVID-19-induced myocardial injury and mortality.
    Life Sci. 2020 Sep 9:118400. doi: 10.1016/j.lfs.2020.118400.
    PubMed     Abstract available


    August 2020
  21. CACCIAPUOTI S, De Rosa A, Gelzo M, Megna M, et al
    Immunocytometric analysis of COVID patients: A contribution to personalized therapy?
    Life Sci. 2020 Aug 29:118355. doi: 10.1016/j.lfs.2020.118355.
    PubMed     Abstract available


  22. CHEUDJEU A
    Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19.
    Life Sci. 2020;260:118335.
    PubMed     Abstract available


  23. WANG F, Zheng S, Zheng C, Sun X, et al
    Attaching clinical significance to COVID-19-associated diarrhea.
    Life Sci. 2020;260:118312.
    PubMed     Abstract available


  24. BHAVANA V, Thakor P, Singh SB, Mehra NK, et al
    COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic.
    Life Sci. 2020 Aug 23:118336. doi: 10.1016/j.lfs.2020.118336.
    PubMed     Abstract available


  25. ELFIKY AA, Baghdady AM, Ali SA, Ahmed MI, et al
    GRP78 targeting: Hitting two birds with a stone.
    Life Sci. 2020 Aug 22:118317. doi: 10.1016/j.lfs.2020.118317.
    PubMed     Abstract available


  26. VARGAS-ALARCON G, Posadas-Sanchez R, Ramirez-Bello J
    Variability in genes related to SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its potential use in association studies.
    Life Sci. 2020;260:118313.
    PubMed     Abstract available


  27. PARVATHANENI V, Gupta V
    Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges.
    Life Sci. 2020 Aug 17:118275. doi: 10.1016/j.lfs.2020.118275.
    PubMed     Abstract available


  28. HOSSEINI FS, Amanlou M
    Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
    Life Sci. 2020;258:118205.
    PubMed     Abstract available


  29. MAHENDIRATTA S, Batra G, Sarma P, Kumar H, et al
    Molecular diagnosis of COVID-19 in different biologic matrix, their diagnostic validity and clinical relevance: A systematic review.
    Life Sci. 2020;258:118207.
    PubMed     Abstract available


  30. MOHAMMAD A, Marafie SK, Alshawaf E, Abu-Farha M, et al
    Structural analysis of ACE2 variant N720D demonstrates a higher binding affinity to TMPRSS2.
    Life Sci. 2020 Aug 5:118219. doi: 10.1016/j.lfs.2020.118219.
    PubMed     Abstract available


  31. DAS S, Anu KR, Birangal SR, Nikam AN, et al
    Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review.
    Life Sci. 2020 Aug 3:118202. doi: 10.1016/j.lfs.2020.118202.
    PubMed     Abstract available


  32. MANSOURABADI AH, Sadeghalvad M, Mohammadi-Motlagh HR, Rezaei N, et al
    The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.
    Life Sci. 2020 Aug 1:118185. doi: 10.1016/j.lfs.2020.118185.
    PubMed     Abstract available


    July 2020
  33. MORRIS G, Bortolasci CC, Puri BK, Olive L, et al
    The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach.
    Life Sci. 2020 Jul 30:118166. doi: 10.1016/j.lfs.2020.118166.
    PubMed     Abstract available


  34. SHARMA K, Morla S, Goyal A, Kumar S, et al
    Computational guided drug repurposing for targeting 2'-O-ribose methyltransferase of SARS-CoV-2.
    Life Sci. 2020 Jul 29:118169. doi: 10.1016/j.lfs.2020.118169.
    PubMed     Abstract available


  35. AKBARI H, Tabrizi R, Lankarani KB, Aria H, et al
    The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
    Life Sci. 2020 Jul 28:118167. doi: 10.1016/j.lfs.2020.118167.
    PubMed     Abstract available


  36. SUT BB
    Molecular profiling of immune cell-enriched Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) interacting protein USP13.
    Life Sci. 2020 Jul 28:118170. doi: 10.1016/j.lfs.2020.118170.
    PubMed     Abstract available


  37. ZHANG J, Wang M, Ding W, Wan J, et al
    The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future.
    Life Sci. 2020;257:118142.
    PubMed     Abstract available


  38. PANIRI A, Akhavan-Niaki H
    Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation.
    Life Sci. 2020 Jul 18:118114. doi: 10.1016/j.lfs.2020.118114.
    PubMed     Abstract available


  39. ZUCKERBERG J, Shaik M, Nelin TD, Widmeier K, et al
    A lung for all: Novel mechanical ventilator for emergency and low-resource settings.
    Life Sci. 2020 Jul 17:118113. doi: 10.1016/j.lfs.2020.118113.
    PubMed     Abstract available


  40. JAFARZADEH A, Chauhan P, Saha B, Jafarzadeh S, et al
    Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
    Life Sci. 2020 Jul 17:118102. doi: 10.1016/j.lfs.2020.118102.
    PubMed     Abstract available


  41. JAMWAL S, Gautam A, Elsworth J, Kumar M, et al
    An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic.
    Life Sci. 2020 Jul 17:118105. doi: 10.1016/j.lfs.2020.118105.
    PubMed     Abstract available


  42. ABBASIFARD M, Khorramdelazad H
    The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics.
    Life Sci. 2020;257:118097.
    PubMed     Abstract available


  43. HAZRA S, Chaudhuri AG, Tiwary BK, Chakrabarti N, et al
    Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.
    Life Sci. 2020 Jul 14:118096. doi: 10.1016/j.lfs.2020.118096.
    PubMed     Abstract available


  44. ABDIN SM, Elgendy SM, Alyammahi SK, Alhamad DW, et al
    Tackling the cytokine storm in COVID-19, challenges, and hopes.
    Life Sci. 2020 Jul 11:118054. doi: 10.1016/j.lfs.2020.118054.
    PubMed     Abstract available


  45. BEHL T, Kaur I, Bungau S, Kumar A, et al
    The dual impact of ACE2 in COVID-19 and ironical actions in geriatrics and pediatrics with possible therapeutic solutions.
    Life Sci. 2020;257:118075.
    PubMed     Abstract available


  46. BHARADWAJ S, Lee KE, Dwivedi VD, Kang SG, et al
    Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M(pro) via combinatorial molecular simulation calculations.
    Life Sci. 2020;257:118080.
    PubMed     Abstract available


  47. HAJIVALILI M, Hosseini M, Haji-Fatahaliha M
    Gaining insights on immune responses to the novel coronavirus, COVID-19 and therapeutic challenges.
    Life Sci. 2020 Jul 9:118058. doi: 10.1016/j.lfs.2020.118058.
    PubMed     Abstract available


  48. YAVARPOUR-BALI H, Ghasemi-Kasman M
    Update on neurological manifestations of COVID-19.
    Life Sci. 2020 Jul 8:118063. doi: 10.1016/j.lfs.2020.118063.
    PubMed     Abstract available


  49. STERNBERG A, Naujokat C
    Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination.
    Life Sci. 2020 Jul 6:118056. doi: 10.1016/j.lfs.2020.118056.
    PubMed     Abstract available


    June 2020
  50. BENITEZ-CARDOZA CG, Vique-Sanchez JL
    Potential inhibitors of the interaction between ACE2 and SARS-CoV-2 (RBD), to develop a drug.
    Life Sci. 2020;256:117970.
    PubMed     Abstract available


  51. PANDEY SC, Pande V, Sati D, Upreti S, et al
    Vaccination strategies to combat novel corona virus SARS-CoV-2.
    Life Sci. 2020;256:117956.
    PubMed     Abstract available


  52. HAGE-MELIM LIDS, Federico LB, de Oliveira NKS, Francisco VCC, et al
    Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.
    Life Sci. 2020;256:117963.
    PubMed     Abstract available


  53. BANU N, Panikar SS, Leal LR, Leal AR, et al
    Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications.
    Life Sci. 2020;256:117905.
    PubMed     Abstract available


  54. SIMKO F, Reiter RJ
    Is melatonin deficiency a unifying pathomechanism of high risk patients with COVID-19?
    Life Sci. 2020;256:117902.
    PubMed    


  55. KHODIR AE, Samra YA, Said E
    A novel role of nifuroxazide in attenuation of sepsis-associated acute lung and myocardial injuries; role of TLR4/NLPR3/IL-1beta signaling interruption.
    Life Sci. 2020 Jun 3:117907. doi: 10.1016/j.lfs.2020.117907.
    PubMed     Abstract available


  56. YAZDANPANAH F, Hamblin MR, Rezaei N
    The immune system and COVID-19: Friend or foe?
    Life Sci. 2020 Jun 2:117900. doi: 10.1016/j.lfs.2020.117900.
    PubMed     Abstract available


  57. PANDEY A, Nikam AN, Shreya AB, Mutalik SP, et al
    Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements.
    Life Sci. 2020 Jun 1:117883. doi: 10.1016/j.lfs.2020.117883.
    PubMed     Abstract available


    May 2020
  58. BANERJEE A, Czinn SJ, Reiter RJ, Blanchard TG, et al
    Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19.
    Life Sci. 2020;255:117842.
    PubMed     Abstract available


  59. TONG PB, Lin LY, Tran TH
    Coronaviruses pandemics: Can neutralizing antibodies help?
    Life Sci. 2020 May 22:117836. doi: 10.1016/j.lfs.2020.117836.
    PubMed     Abstract available


  60. GURUNG AB, Ali MA, Lee J, Farah MA, et al
    Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M(pro) enzyme through in silico approach.
    Life Sci. 2020;255:117831.
    PubMed     Abstract available


  61. RENU K, Prasanna PL, Valsala Gopalakrishnan A
    Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review.
    Life Sci. 2020;255:117839.
    PubMed     Abstract available


  62. MARTIN GIMENEZ VM, Inserra F, Tajer CD, Mariani J, et al
    Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment.
    Life Sci. 2020;254:117808.
    PubMed     Abstract available


  63. KERMALI M, Khalsa RK, Pillai K, Ismail Z, et al
    The role of biomarkers in diagnosis of COVID-19 - A systematic review.
    Life Sci. 2020 May 13:117788. doi: 10.1016/j.lfs.2020.117788.
    PubMed     Abstract available


  64. KERMALI M, Khalsa RK, Pillai K, Ismail Z, et al
    The role of biomarkers in diagnosis of COVID-19 - A systematic review.
    Life Sci. 2020;254:117788.
    PubMed     Abstract available


  65. PATIL VM, Singhal S, Masand N
    A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials.
    Life Sci. 2020;254:117775.
    PubMed     Abstract available


  66. POOLADANDA V, Thatikonda S, Godugu C
    The current understanding and potential therapeutic options to combat COVID-19.
    Life Sci. 2020 May 8:117765. doi: 10.1016/j.lfs.2020.117765.
    PubMed     Abstract available


    April 2020
  67. HERRERA EA, Gonzalez-Candia A
    Comment on Melatonin as a potential adjuvant treatment for COVID-19.
    Life Sci. 2020 Apr 30:117739. doi: 10.1016/j.lfs.2020.117739.
    PubMed    


  68. BABAPOOR-FARROKHRAN S, Gill D, Walker J, Rasekhi RT, et al
    Myocardial injury and COVID-19: Possible mechanisms.
    Life Sci. 2020;253:117723.
    PubMed     Abstract available


  69. SALLES C
    Correspondence COVID-19: Melatonin as a potential adjuvant treatment.
    Life Sci. 2020 Apr 22:117716. doi: 10.1016/j.lfs.2020.117716.
    PubMed    


  70. SHAH B, Modi P, Sagar SR
    In silico studies on therapeutic agents for COVID-19: Drug repurposing approach.
    Life Sci. 2020 Apr 9:117652. doi: 10.1016/j.lfs.2020.117652.
    PubMed     Abstract available


    March 2020
  71. ELFIKY AA
    Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study.
    Life Sci. 2020 Mar 25:117592. doi: 10.1016/j.lfs.2020.117592.
    PubMed     Abstract available


    February 2020
  72. ELFIKY AA
    Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
    Life Sci. 2020 Feb 28:117477. doi: 10.1016/j.lfs.2020.117477.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO COVID-19 is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: